The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
From recent Q&A on Directors Talk:
"We’re starting our COVID proof of concept in vivo work imminently and that’s for our un-optimised version of the Nuvec system so once we have this data, we shouldn’t take too long, we will then look to do another follow on in vivo study with optimised versions of the product. So, we’re running the optimisation work in parallel to that first study so that we can then pull all the learnings together to come up with a further proof of concept work because the continued updates of the work as we go, enables us to keep reaching out to people to say, this is how Nuvec works.
So, investors can expect a lot more news on both the COVID proof of concept work and the optimisation work and well also be updating progress on the oral programme as soon as we get it, as it goes forward.
Finally, we’ll give an update on other applications, on top of both oral and injectable vaccines, that we see and will be a priority for the development of Nuvec".
I would tend to agree. The RNS was a bit 'meh' for me with very little detail as to what is going on behind the scenes and no fixed timelines to anything. Industry collaborations/JVs are the main catalysts for this share which essentially will go hand in hand with any major breakthroughs in their studies I would imagine. I personally thought the note about vaccine storage not requiring freezing possibly warranted a separate RNS and to me, sounds like it could have major benefit for any big pharma vehicle. Ultimately it needs a major to step in and say "We're gonna use this" before we start seeing a rerate. Nigel has got a job on to commercialise Nuvec and time/money is running out.
hardly P&D - its called "buy low, sell high". What all good investors do. If i'd made 500% on a previous investment I think i'd take half off the table too given I probably still have a shedload of warrants to cash in..... :p
they haven't bought more. they are selling
been on work calls all day... what a nice surprise when I looked at my phone! Looks like the China Club Q&A went well :))
The presentation for Friday is pre-recorded here: https://www.miningindaba.com/Page/mkango-resources (see video). The session on Friday morning 9:46am GMT is a 12 minute Q&A which you can view here on the day: https://www.bigmarker.com/hyve/Sesson-3-Live-Q-A and it will also be recorded.
lol there really are some fools on this board.... PJ took a few in the 0.2 placing and probably took a few more in the 0.6 one which are still to be issued... anyone who thinks he wouldn't sell a few based on a 2 or 3 bags profit is delusional!
What do you think of Nicole's appointment Ken?
https://www.linkedin.com/in/nicole-galloway-warland-9272a71b/?originalSubdomain=au
https://twitter.com/CMA_Minerals/status/1313020743240822784?s=20
deadline is 6 months from 10 June for RTO or 6 million fundraise as per standard AIM rules for cash shells.
https://www.lincolninternational.com/transactions/kuala-lumpur-kepong-berhad-has-acquired-equatorial-palm-oil/
Thoughts? Now that KLK own PAL... what next? They haven't bought a majority stake for nothing...
when you put it like that he'd do well to acquire them on the open market now and then flip the warrants if we go above 2p. Other than that it isn't worth doing.
I would be very surprised if he exercises them given the timeframe between now and 2 Nov - not enough time to see a stable floor in the SP with which to make a judgement on whether or not they could be traded for a profit. You never know, stranger things have happened on AIM. The upside is, if he doesn't take them then it's less dilution for the rest of us, so not a bad thing.
surprised this hasn't gone to zero yet. they're going into liquidation within 12 months. Mark my words.
anyone else find it a bit weird they are doing an investor presentation next week so close after the last one?... further material news inbound?....
What and learn? learn how to spell? ;-)
BOOOOOOOOOOOOOOM
massive massive difference in terms of where the projects are at with PRE and MKA. DYOR and it is easy to see why. I looked at PRE at 30p and wasn't sure how quickly they were going to move with the new resource estimate but boy they have pulled the cat out the bag there bigtime. Looks a quality outfit. MKA will catch up but it will take a lot longer because of the BFS delay and it doesn't smell too good about why it has been delayed for so long. MKA management used Covid as an excuse but I don't buy it. That is why we are priced so low. A lot can happen in a year.
looks like other link is blocked - check N4 twitter: https://twitter.com/n4pharma/status/1305480508319641600?s=20